KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Depreciation and Depletion (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Depreciation and Depletion for 6 consecutive years, with $5.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation and Depletion rose 142.77% year-over-year to $5.2 million, compared with a TTM value of $18.4 million through Dec 2025, up 47.08%, and an annual FY2025 reading of $18.4 million, up 47.08% over the prior year.
  • Depreciation and Depletion was $5.2 million for Q4 2025 at AbCellera Biologics, up from $4.3 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $5.2 million in Q4 2025 and bottomed at $800000.0 in Q1 2021.
  • Average Depreciation and Depletion over 5 years is $2.9 million, with a median of $2.9 million recorded in 2023.
  • The sharpest move saw Depreciation and Depletion soared 3536.36% in 2021, then tumbled 45.21% in 2024.
  • Year by year, Depreciation and Depletion stood at $1.3 million in 2021, then surged by 115.38% to $2.8 million in 2022, then skyrocketed by 39.29% to $3.9 million in 2023, then plummeted by 45.21% to $2.1 million in 2024, then surged by 142.77% to $5.2 million in 2025.
  • Business Quant data shows Depreciation and Depletion for ABCL at $5.2 million in Q4 2025, $4.3 million in Q3 2025, and $4.5 million in Q2 2025.